Featured Research

from universities, journals, and other organizations

New Vaccine Being Tested In Prostate Cancer Patients

Date:
November 23, 1998
Source:
American Chemical Society
Summary:
Chemists at the Sloan-Kettering Institute for Cancer Research have created a novel vaccine they hope will thwart prostate cancer. Now in early human trials, the vaccine is the first made synthetically to target abundant, but elusive, carbohydrates on the surface of tumor cells.

Chemists at the Sloan-Kettering Institute for Cancer Research have created a novel vaccine they hope will thwart prostate cancer. Now in early human trials, the vaccine is the first made synthetically to target abundant, but elusive, carbohydrates on the surface of tumor cells.

The development will be outlined in the November 20 Web edition of the Journal of the American Chemical Society, published by the American Chemical Society, the world's largest scientific society. It is scheduled to appear in the print version of the peer-reviewed journal on November 25.

Using vaccines to stimulate an immune response against cancer typically focuses on proteins, which are relatively easy to make but often arelodged within cells and not easily accessible to antibodies. Most of the good targets, or antigens, on a cancer cell's surface are not proteins, however. Instead they are small, difficult to synthesize carbohydrates whose immunogenicity is not well-understood.

"Normally the carbohydrates are much more complex in normal cells. In cancer cells they're often very different," says lead author and Sloan Kettering Institute for Cancer Research chemist Scott D. Kuduk, Ph.D. The difference should enable scientists to exclusively target cancer.

Kuduk, who works in the lab of Kettering Chair and Director of Bioorganic Chemistry, Samuel J. Danishefsky, Ph.D., says their group successfully synthesized two key tumor carbohydrate antigens -- called TF and Tn. They then clustered the antigens as they occur naturally and attached them to proteins which help produce an immune response. "Through chemistry, we were able to make substantial quantities of the material that allowed us to then do the testing," adds Kuduk. In mice, the Tn-protein complex was especially effective at triggering antibody production.

"It's a wonderful antigen for prostate cancer because Tn is one of the main antigens on prostate cancer cells," according to co-author and Sloan Kettering Immunologist Philip O. Livingston, M.D., who calls the advance "more promising than other approaches."

The new vaccine is being given to patients who have undergone prostate cancer surgery, hoping to ward off a recurrence. Though it is too early to know whether a series of vaccinations will provide an adequate defense, Livingston says patients are definitely producing antibodies against Tn. Scientists hope the vaccines will specifically attack prostate cancer cells, thereby permanently curbing cancer and reducing the side effects usually associated with chemotherapy.

###

A nonprofit organization with a membership of more than 155,000 chemists and chemical engineers, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "New Vaccine Being Tested In Prostate Cancer Patients." ScienceDaily. ScienceDaily, 23 November 1998. <www.sciencedaily.com/releases/1998/11/981120075658.htm>.
American Chemical Society. (1998, November 23). New Vaccine Being Tested In Prostate Cancer Patients. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/1998/11/981120075658.htm
American Chemical Society. "New Vaccine Being Tested In Prostate Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/1998/11/981120075658.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins